After melanoma and non-small cell lung cancer, the FDA has granted Breakthrough Therapy status to pembrolizumab in advanced colorectal cancer patients with mismatched repair deficiency.
When the results of the KEYNOTE-164 trial were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) earlier this year, they created quite a fuss. One of the lead authors on the paper, Dung T. Le, MD, assistant professor of oncology at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, showed results that claimed efficacy of pembrolizumab (Keytruda) in colorectal cancer (CRC) patients deficient in mismatch repair (mismatch repair deficiency or MMRD), which leads to microsatellite instability. These results have led to the drug being granted it’s third Breakthrough Therapy designation, this time in advanced colorectal cancer patients with microsatellite instability high. Pembrolizumab already has Breakthrough designation in advanced melanoma and advanced non-small cell lung cancer.
The results presented at ASCO, subsequently published in the New England Journal of Medicine, were from the phase 2 study conducted to evaluate the clinical activity of the anti—PD-1 monoclonal antibody, pembrolizumab, in 41 patients—with and without MMRD—who had previously been treated for progressive metastatic disease. The patients were divided into 3 cohorts: cohort A, CRC patients deficient in mismatch repair; cohort B, CRC patients proficient in mismatch repair; and cohort C, non-CRC patient deficient in mismatch repair. The primary end points, said Dr Le, were immune-related objective response rate (irORR) and immune-related progression-free survival (irPFS) at 20 weeks. A majority of the patients enrolled had 2 or more prior therapies.
At 20 weeks, the irORR for cohort A was 62% and the disease control rate (DCR) was 92%; for cohort B, the irORR was 0% and DCR was 16%; for cohort C, the irORR was 60% and DCR was 70%. Durable disease control was achieved in cohort A, with most responses lasting over a year. While progression-free survival (PFS) had not been reached in cohorts A and C, PFS was 2.3 months in cohort B. Adverse events observed were primarily of low grade.
Senior study author Luis A. Diaz, Jr, MD, associate professor of oncology at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, said in an interview with The American Journal of Managed Care that he expects pembrolizumab to be standard of care in colon cancer in the near future and that mismatched repair testing will be standard of care for these patients as well. “I suspect that up front, when you get diagnosed with advanced colon cancer, you’re going to get mismatched repair testing,” Dr Diaz said.
“We are committed to understanding the full potential of Keytruda to help patients with a broad range of difficult-to-treat cancers,” Roger M. Perlmutter, MD, PhD, president, Merck Research Laboratories, said in a press release. “The data investigating the use of Keytruda in patients with advanced colorectal cancer whose tumors have substantial evidence of mismatch DNA repair defects have been encouraging, and we appreciate the opportunity that this FDA Breakthrough Therapy Designation provides us to accelerate our effort to bring Keytruda to these patients.”
The company is planning a phase 3 study (KEYNOTE-177) in treatment-naïve CRC patients.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More